Lexicon Pharma to Cut Around 45% of Workforce; CEO to Depart

Lexicon Pharmaceuticals (NASDAQ: LXRX  ) is narrowing its business focus in an effort that will lead to a substantial reduction in head count, and its CEO will also be departing.

The company announced that it will concentrate its resources on late-stage drug development programs. For the most part, this consists of two treatments it's currently developing -- one for diabetes, and the other for carcinoid syndrome. As a result of this new concentration, around 115 employees will no longer work at the firm. That's roughly 45% of the present workforce.

With these measures, Lexicon says it will reduce its expenses by a net amount of approximately $14 million for the balance of its fiscal 2014 and around $22 million annually going forward.

In the press release announcing the news, the firm quoted CEO Arthur Sands as saying that the new focus "increases Lexicon's financial strength and will enable the company to more effectively advance our key late-stage programs and to prepare for commercialization."

Sands will not stay in his current position. In the press release, the company revealed that he has "indicated his intention to develop a succession plan with the board of directors to identify a new chief executive officer for the next phase of Lexicon's growth." Sands will stay in his position until the board finds his replacement. 

Last month, Lexicon's share price swooned after the company reported disappointing results from its phase 2 study of LX1033, a treatment for irritable bowel syndrome. 

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2793249, ~/Articles/ArticleHandler.aspx, 9/3/2015 3:40:21 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Eric Volkman

Eric has been writing about stocks and finance since the mid-1990s, when he lived in Prague, Czech Republic. Over the course of a varied career, he has also been a radio newscaster, an investment banker, and a bass player in a selection of rock and roll bands. A native New Yorker, he currently lives in Los Angeles.

Today's Market

updated Moments ago Sponsored by:
DOW 16,378.24 26.86 0.16%
S&P 500 1,951.03 2.17 0.11%
NASD 4,744.45 -5.53 -0.12%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/3/2015 3:24 PM
LXRX $12.24 Down -0.40 -3.16%
Lexicon Pharmaceut… CAPS Rating: **